Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.720 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
NASDAQ: CRBU Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Caribou Biosciences, Inc. ↗
San Diego, CA -- (SBWIRE) -- 02/28/2023 -- An investor, who purchased shares of Caribou Biosciences, Inc. (NASDAQ: CRBU), filed a lawsuit over alleged violations of Federal Securities Laws by Caribou... 
Via SBWire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
WHY: New York, NY - (NewMediaWire) - February 26, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant... 
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, A LEADING AND RANKED FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Caribou Biosciences, Inc. (CRBU) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Caribou Biosciences, Inc.
From Robbins LLP
Via Business Wire
News headline image
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Lowey Dannenberg Notifies Caribou Biosciences, Inc. (Nasdaq: CRBU) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
CARIBOU ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Caribou Biosciences, Inc. (CRBU) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Caribou Biosciences, Inc. (CRBU)
From Robbins LLP
Via Business Wire
News headline image
CRBU INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CRBU
From Rosen Law Firm
Via Business Wire
News headline image
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
News headline image
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗
-Clinical Data Due Next Week at ASH- 
Via Benzinga
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug... 
Via FinancialNewsMedia
News headline image
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.